Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XyloCore versus standard glucose peritoneal dialysis solutions in end-stage renal disease
2019-004183-21Phase 3Active
- Sponsor
- Iperboreal Pharma
- Start
- Mar 2022
- Modality
- Gene Therapies
- Countries
- 1
01
Overview
Phase 3 trial of encoberminogene rezmadenovec in end-stage kidney disease (ESKD) (2 arms), sponsored by Iperboreal Pharma. Primary endpoint: Total weekly Kt/Vurea after 24 weeks. Started Mar 2022; status: active.
02
Drugs
encoberminogene rezmadenovec
03
Conditions
end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on 2019-004183-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004183-21.